TrialPath
Recruiting

The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma

NCT07565285 · Primmune Therapeutics, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2 Study to Investigate the Activity of Neoadjuvant PRTX007 Combined With Pembrolizumab in Participants With Stage III Melanoma (INFLECTION-003)
About this study
This study investigates whether combining the TLR7 agonist PRTX007 with pembrolizumab enhances immune-mediated tumor response in the neoadjuvant setting for Stage III melanoma, with the goal of improving pathologic response rates and clinical outcomes while maintaining an acceptable safety profile. Design This is a Phase 2, multi-center, open-label, single-arm study conducted in Australia. The study will enroll approximately 48 participants with resectable Stage III melanoma. The study consists of two parts: * Part A: 24 participants will be enrolled, including an initial dose-escalation safety run-in using a 3+3 design to evaluate tolerability and dose-limiting toxicities. * Part B: An additional 24 participants will be enrolled if sufficient activity is observed in Part A. Treatment Plan Participants will receive neoadjuvant therapy consisting of: * PRTX007: Oral administration for 3 days on and 4 days off per week for 9 cycles (7-day cycles) * Pembrolizumab: 200 mg intravenous infusion every 3 weeks for 3 cycles Following completion of neoadjuvant therapy, participants will undergo definitive surgical resection. Post-surgical treatment will be response-adapted: * Participants achieving MPR may receive observation or pembrolizumab alone * Participants without MPR will receive adjuvant PRTX007 in combination with pembrolizumab
Eligibility criteria
Inclusion Criteria: * Adults aged 18 years or older * Histologically confirmed, resectable Stage III cutaneous melanoma. * Candidate for curative-intent surgical resection * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Adequate organ function * Able to provide written informed consent Exclusion Criteria: * Prior systemic therapy for melanoma, including immunotherapy * Uveal melanoma or mucosal melanoma. * Active autoimmune disease requiring systemic treatment * Primary immunodeficiency or use of systemic immunosuppressive therapy * Women who are pregnant or breastfeeding * Recent treatment with another investigational therapy * Any condition that, in the opinion of the investigator, would interfere with study participation or safety
Study design
Enrollment target: 48 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-07-01
Estimated completion: 2029-06
Last updated: 2026-10-23
Interventions
Drug: PRTX007Drug: Pembrolizumab
Primary outcomes
  • • Major Pathologic Response (MPR) Rate (At time of surgical resection (approximately 9 weeks after initiation of treatment))
Sponsor
Primmune Therapeutics, Inc. · industry
Contacts & investigators
ContactGunjan Mody · contact · gunjan.mody@novotech-cro.com · +61 2 9199 9596
All locations (7)
Calvary Mater NewcastleRecruiting
Waratah, New South Wales, Australia
Cairns And Hinterland Hospital And Health ServiceNot Yet Recruiting
Cairns, Queensland, Australia
Gallipoli Medical ResearchNot Yet Recruiting
Greenslopes, Queensland, Australia
Princess Alexandra HospitalNot Yet Recruiting
Woolloongabba, Queensland, Australia
Peter MacCallum Cancer CentreRecruiting
Melbourne, Victoria, Australia
One Clinical Research Pty LtdRecruiting
Nedlands, Western Australia, Australia
Sir Charles Gairdner HospitalNot Yet Recruiting
Nedlands, Western Australia, Australia